All Posts: clinical trials
-
Ruesch Symposium Participants Encourage Patients to Consider Clinical Trials
(December 2, 2022) — After being diagnosed with pancreatic cancer in April 2021, Jan Baird-Adams, a librarian from Maryland, had lots of questions for her oncologist, Marcus Noel, MD, associate professor of oncology and director of the Clinical Research Management Office at Georgetown Lombardi Comprehensive Cancer Center. “Dr. Noel and his staff were incredibly kind […]
Category: Lombardi Stories
-
The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology
MILWAUKEE (October 6, 2022)— No uniform method has been established to predict the probability of success for individual clinical trials. To help identify clinical trials with a high likelihood of offering benefit to patients, the Society for Immunotherapy of Cancer (SITC) brought together a team of experts in immuno-oncology to create a conceptual framework for […]
Category: News Release
-
Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
The findings, coupled with results from another recent clinical trial, mark significant advances in the treatment of melanoma. WASHINGTON (September 27, 2022) — A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received […]
Category: News Release
-
Trial Stopped Early: Giving Immunotherapy Before Targeted Rx Improves Survival in Advanced Melanoma
WASHINGTON (November 15, 2021) — More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment with targeted therapies. The finding comes from a clinical trial that was stopped early […]
Category: News Release
-
Clinical Trial Result Leads to New Treatment Option for Hard-to-Treat Breast Cancer
(June 4, 2021) — A clinical trial exploring a new treatment for breast cancer found that women with a hard-to-treat form of the disease lived longer without the disease coming back following treatment. The trial was conducted at sites around the world, including Georgetown Lombardi Comprehensive Cancer Center. “This finding represents a significant step forward […]
Category: Lombardi Stories
-
Glynda’s Story: A Chance to Advance Treatment for Aggressive Cancer
(January 11, 2021) — Inspired by the kindness, proficiency and dedication of her health care team at Georgetown Lombardi Comprehensive Cancer Center, Glynda Brown, a 52-year-old Maryland resident, felt determined to “pay it forward” and make a positive difference for future patients by participating in a clinical trial after she was diagnosed with triple-negative breast […]
Category: Lombardi Stories
-
FDA Approves Lung Cancer Drug Supported by Georgetown Lombardi Research
(September 14, 2020) — Julie Shanholtz was having an uneventful summer in 2017 working full time with the same employer she’d had for the past 30 years when she developed an “odd cough” that quickly became severe, but no other symptoms. “I had always been very active and healthy — and didn’t smoke,” the 54-year-old […]
Category: Lombardi Stories
-
Georgetown Lombardi Clinical Trial Helps Advance Use of Immunotherapy in Liver Cancer
(January 4, 2020) — In August of 2016, Dan Hilton arrived at MedStar Georgetown University Hospital to be evaluated for a liver transplant. He had been diagnosed with cirrhosis, the result of a hepatitis C infection contracted many years earlier. After multiple tests, he received unexpected news; the doctors found tumors on his liver. They […]
Category: Lombardi Stories
-
Palbociclib is Safe for Women with Advanced Breast Cancer Who Have Unique Gene Alteration
WASHINGTON (December 11, 2019) — Women who receive palbociclib (Ibrance®) to treat their advanced breast cancer and have a gene alteration that can lead to a condition known as benign ethnic neutropenia (BEN) can safely receive the drug without major concerns of developing infections associated with neutropenia, or low white blood cell counts, say Georgetown Lombardi […]
Category: News Release
-
Nearly One-Quarter of Completed Lung Cancer Clinical Trial Results Are Not Published
WASHINGTON (November 6, 2019) — Despite the lengthy time and money commitments that are required to conduct clinical trials, a new analysis has found that up to one-fourth of completed lung cancer clinical trial results are not published, thereby depriving patients, the research community and the public of a complete picture of the current state of […]
Category: News Release